Journal
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Volume 11, Issue 1, Pages 31-38Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nano.2014.07.004
Keywords
Hybrid nanomaterials; Nanomedicine; Cancer chemoradiotherapy; Cisplatin; Polysilsesquioxane; Lung cancer; Silica
Funding
- National Institutes of Health [U54-CA151652, U01-CA151455, R01CA178748-01]
- National Institutes of Health/NCI K12 Career Development Award [5-K12-CA120780-01-05]
- National Institutes of Health Center for Nanotechnology [1-U54-CA151652-01]
- Lung Cancer Foundation
- University Research Fund
Ask authors/readers for more resources
Chemoradiotherapy is a well-established treatment paradigm in oncology. There has been strong interest in identifying strategies to further improve its therapeutic index. An innovative strategy is to utilize nanoparticle (NP) chemotherapeutics in chemoradiation. Since the most commonly utilized chemotherapeutic with radiotherapy is cisplatin, the development of an NP cisplatin for chemoradiotherapy has the highest potential impact on this treatment. Here, we report the development of an NP comprised of polysilsesquioxane (PSQ) polymer crosslinked by a cisplatin prodrug (Cisplatin-PSQ) and its utilization in chemoradiotherapy using non-small cell lung cancer as a disease model. Cisplatin-PSQ NP has an exceptionally high loading of cisplatin. Cisplatin-PSQ NPs were evaluated in chemoradiotherapy in vitro and in vivo. They demonstrated significantly higher therapeutic efficacy when compared to cisplatin. These results suggest that the Cisplatin-PSQ NP holds potential for clinical translation in chemoradiotherapy. From the Clinical Editor: These authors present an innovative strategy utilizing the presence of platinum in nanoparticle chemotherapeutics for chemoradiation, demonstrating its efficacy in a non-small cell lung cancer model. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available